PCM
SEEL

Penserra Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Penserra Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-89
Closed -$233K – 1264
2022
Q2 		$233K Sell
89
-8
-8% -$20.8K 0.01% 653
2022
Q1 		$235K Buy
97
+14
+17% +$60.2K 0.01% 688
2021
Q4 		$521K Buy
83
+16
+24% +$123K 0.01% 528
2021
Q3 		$624K Buy
67
+40
+148% +$344K 0.01% 454
2021
Q2 		$273K Buy
+27
New +$444K 0.01% 582

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Penserra Capital Management's SEEL Position: Q3 2022 in Review

Penserra Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2022, closing a stake of 89 shares — an estimated $233K sold.

Penserra Capital Management first reported a position in SEEL in Q2 2021 and held it in 5 quarters. The position peaked at $624K in Q3 2021. 68 funds tracked by Wall St. Rank hold SEEL as of Q3 2022.

  • Penserra Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 89 Seelos Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $233K.
  • Penserra Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Penserra Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $624K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.